Home › Anaplastic Large-Cell Lymphoma › Washington › Seattle
Anaplastic Large-Cell Lymphoma clinical trials in Seattle, WA
3 studies for Anaplastic Large-Cell Lymphoma are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- University of Washington Fred Hutch Cancer Center, Seattle
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingPhase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RecruitingPhase 2Healthy volunteers welcome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Anaplastic Large-Cell Lymphoma trials in other cities
- Atlanta, GA4 studies
- St. Louis, MO4 studies
- Houston, TX4 studies
- Durham, NC4 studies
- Rochester, MN4 studies
- Boston, MA3 studies
- Philadelphia, PA3 studies
- Baldwin Park, CA3 studies
- Columbus, OH3 studies
- New York City, NY3 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Myelodysplastic Syndromes21 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.